Assessment of long-term immunological and pulmonary safety of inhaled human insulin with up to 24 months of continuous therapy

Current Medical Research and Opinion

Volumn 24, Issue 11, 2008, Pages 3073-3083

  Cefalu, William T ^a   Bohannon, Nancy J V ^b   Fineberg, S Edwin ^c,d   Teeter, John G ^e   Schwartz, Pamela F ^e   Reis, Joann M ^e   Krasner, Alan S ^e  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Efficacy; Inhaled insulin; Safety; Type 1 diabetes; Type 2 diabetes

Indexed keywords

CARBON MONOXIDE; HUMAN INSULIN; INSULIN ANTIBODY; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; RECOMBINANT HUMAN INSULIN;

ADULT; ANTIGEN BINDING; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIABETIC PATIENT; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; GLYCEMIC CONTROL; GROUPS BY AGE; HUMAN; HYPOGLYCEMIA; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; LUNG ALVEOLUS CARBON DIOXIDE TENSION; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNE SYSTEM; INSULIN; LUNG; MALE; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649403313     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802421657     Document Type: Article

References (22)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progres1sion of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986 (Pubitemid 23307905)
2. UK Prospective Diabetes Study. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853 (Pubitemid 28416718)
3. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy: the basis of patient reluctance. Diabetes Care 1997;20:292-298 (Pubitemid 27098212)
4. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20
5. DeFronzo RA, Bergenstal RM, Cefalu WT, et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 2005;28:1922-1928 (Pubitemid 41060964)
6. Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2005;143:549-558 (Pubitemid 41476551)
7. Skyler JS, Jovanovic L, Klioze S, et al. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care 2007;30:579-585 (Pubitemid 46354337)
8. Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2356-2362 (Pubitemid 39281385)
9. Quattrin T, Belanger A, Bohannon NJ, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2622-2627 (Pubitemid 39441461)
10. Skyler JS, Weinstock RS, Raskin P, et al. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005;28:1630-1635 (Pubitemid 40923076)
11. Rosenstock J, Foyt H, Klioze S, et al. Inhaled human insulin (Exubera) therapy shows sustained efficacy and is well tolerated over a 2-year period in patients with type 2 diabetes (T2DM) [abstract]. Diabetes 2006;55(Suppl 1):A26
12. Fineberg SE, Kawabata T, Finco-Kent D, et al. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes: an analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 2005;90:3287-3294 (Pubitemid 41014288)
13. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique - 1995 update. Am J Respir Crit Care Med 1995;152:2185-2198
14. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995;152:1107-1136
15. Barnett AH, Lange P, Dreyer M, et al. Long-term tolerability of inhaled human insulin (Exubera®) in patients with poorly controlled type 2 diabetes. Int J Clin Pract 2007;61:1614-1625 (Pubitemid 47404394)
16. Teeter JG, Riese RJ. Dissociation of lung function changes with humoral immunity during inhaled human insulin therapy. Am J Respir Crit Care Med 2006;173:1194-1200 (Pubitemid 43848388)
17. Skyler JS, Jovanovic L, Klioze S, et al. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care 2007;30:579-585 (Pubitemid 46354337)
18. Liu MC, Riese RJ, Van Gundy K, et al. Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes. Eur Respir J 2008;32:180-188
19. Davis WA, Knuiman M, Kendall P, et al. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2004;27:752-757 (Pubitemid 38280545)
20. Weynand B, Jonckheere A, Frans A, et al. Diabetes mellitus induces a thickening of the pulmonary basal lamina. Respiration 1999;66:14-19 (Pubitemid 29089987)
21. Farina J, Furio V, Fernandez-Acenero MJ, et al. Nodular fibrosis of the lung in diabetes mellitus. Virchows Arch 1995;427:61-63
22. Skyler JS, for the Exubera Phase 3 Study Group. Efficacy and safety of inhaled insulin (Exubera®) compared to subcutaneous insulin therapy in an intensive insulin regimen in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial [abstract]. Diabetes 2002;55(Suppl 2):A134